Dean Quinn

1.7k total citations · 1 hit paper
20 papers, 789 citations indexed

About

Dean Quinn is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Epidemiology. According to data from OpenAlex, Dean Quinn has authored 20 papers receiving a total of 789 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 10 papers in Physiology and 6 papers in Epidemiology. Recurrent topics in Dean Quinn's work include Asthma and respiratory diseases (10 papers), Inhalation and Respiratory Drug Delivery (8 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (6 papers). Dean Quinn is often cited by papers focused on Asthma and respiratory diseases (10 papers), Inhalation and Respiratory Drug Delivery (8 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (6 papers). Dean Quinn collaborates with scholars based in New Zealand, United States and United Kingdom. Dean Quinn's co-authors include Lloyd B. Klickstein, Joan B. Mannick, Guglielmo Roma, David J. Glass, Tea Shavlakadze, Hans Hockey, Kenneth Kulmatycki, Melody K. Morris, Martin Beibel and Weihua Zhou and has published in prestigious journals such as Journal of Allergy and Clinical Immunology, Journal of Hepatology and Science Translational Medicine.

In The Last Decade

Dean Quinn

18 papers receiving 774 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

TORC1 inhibition enhances immune function and reduces infections in the elderly

2018 332 citations Joan B. Mannick, Melody K. Morris et al. Science Translational Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dean Quinn New Zealand	11	403	273	154	136	110	20	789
Vimal Vasu United Kingdom	11	234 0.6×	124 0.5×	130 0.8×	24 0.2×	63 0.6×	23	541
Fahad Al-Ghimlas Kuwait	12	216 0.5×	73 0.3×	202 1.3×	162 1.2×	8 0.1×	21	757
Simon Carson New Zealand	6	162 0.4×	27 0.1×	194 1.3×	172 1.3×	167 1.5×	8	646
Nahid Zareian United Kingdom	8	101 0.3×	39 0.1×	110 0.7×	200 1.5×	26 0.2×	10	605
Margaret F. Doyle United States	19	98 0.2×	160 0.6×	212 1.4×	227 1.7×	5 0.0×	61	1.0k
Unnur Steina Björnsdóttir Iceland	15	461 1.1×	289 1.1×	161 1.0×	122 0.9×	4 0.0×	23	808
Eliezer Burstein Israel	13	51 0.1×	111 0.4×	223 1.4×	58 0.4×	67 0.6×	20	888
Zachary M. Sellers United States	19	53 0.1×	274 1.0×	211 1.4×	58 0.4×	2 0.0×	51	1.0k
Gerald B. Lee United States	3	602 1.5×	354 1.3×	115 0.7×	245 1.8×		6	837
Andrea Schmid Germany	10	86 0.2×	41 0.2×	297 1.9×	57 0.4×	3 0.0×	17	884

Countries citing papers authored by Dean Quinn

Since Specialization

Citations

This map shows the geographic impact of Dean Quinn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dean Quinn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dean Quinn more than expected).

Fields of papers citing papers by Dean Quinn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dean Quinn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dean Quinn. The network helps show where Dean Quinn may publish in the future.

Co-authorship network of co-authors of Dean Quinn

This figure shows the co-authorship network connecting the top 25 collaborators of Dean Quinn. A scholar is included among the top collaborators of Dean Quinn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dean Quinn. Dean Quinn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hammitt, Laura L., Dean Quinn, Ewa Janczewska, et al.. (2023). Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18–49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors. Human Vaccines & Immunotherapeutics. 19(1). 2177066–2177066. 4 indexed citations

Quinn, Dean, Mohammed Bensellam, Nathalie De Schrevel, et al.. (2022). 2139. Immunogenicity, reactogenicity and safety of a Respiratory Syncytial Virus prefusion F (RSVPreF3) candidate vaccine co-administered with the seasonal quadrivalent influenza vaccine in older adults. Open Forum Infectious Diseases. 9(Supplement_2).

Mannick, Joan B., Grace Sock Leng Teo, Dean Quinn, et al.. (2021). Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials. The Lancet Healthy Longevity. 2(5). e250–e262. 72 indexed citations

Hammitt, Laura L., Dean Quinn, Ewa Janczewska, et al.. (2021). 1050. Phase 3 Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by 23valent Pneumococcal Polysaccharide Vaccine 6 Months Later in At-risk Adults Aged 18–49 Years (PNEU-DAY): A Subgroup Analysis by Baseline Risk Factors. Open Forum Infectious Diseases. 8(Supplement_1). S616–S617. 1 indexed citations

Hammitt, Laura L., Dean Quinn, Ewa Janczewska, et al.. (2021). Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18–49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY). Open Forum Infectious Diseases. 9(3). ofab605–ofab605. 11 indexed citations

Aspinall, Richard, Mustafa M. Shennak, Dean Quinn, et al.. (2020). Nidufexor, a non-bile acid FXR agonist, decreases ALT and hepatic fat fraction in patients with NASH after 12 weeks dosing. Journal of Hepatology. 73. S4–S5. 8 indexed citations

Mannick, Joan B., Melody K. Morris, Hans Hockey, et al.. (2018). TORC1 inhibition enhances immune function and reduces infections in the elderly. Science Translational Medicine. 10(449). 332 indexed citations breakdown →

Quinn, Dean, Christopher Barnes, David L. Bourdet, et al.. (2017). Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies. Pulmonary Pharmacology & Therapeutics. 48. 71–79. 31 indexed citations

Hanania, Nicola A., Donald P. Tashkin, Edward Kerwin, et al.. (2017). Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease. Respiratory Medicine. 126. 105–115. 57 indexed citations

10.

Quinn, Dean, J. Paul Seale, Colin Reisner, et al.. (2014). A randomized study of formoterol fumarate in a porous particle metered-dose inhaler in patients with moderate-to-severe COPD. Respiratory Medicine. 108(9). 1327–1335. 10 indexed citations

11.

Kempsford, Rodger, et al.. (2013). The efficacy of once-daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respiratory Medicine. 107(12). 1873–1880. 22 indexed citations

12.

Oliver, Amanda J., et al.. (2013). Modulation of allergen‐induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy. 68(9). 1136–1142. 17 indexed citations

13.

Oliver, Amanda J., et al.. (2012). Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23 h after dosing in adult asthma: a randomised, controlled trial. Clinical and Translational Allergy. 2(1). 11–11. 13 indexed citations

14.

Oliver, Amanda J., et al.. (2012). Efficacy of fluticasone furoate (FF) and vilanterol (VI), separately and in combination (FF/VI), in an allergen challenge model. 40. 2161. 1 indexed citations

15.

Potgieter, Peter D., et al.. (2012). A randomized, crossover study to examine the pharmacodynamics and safety of a new antimuscarinic (TD-4208) in COPD. 40. 2878. 4 indexed citations

16.

Reisner, Colin, Charles Fogarty, Selwyn Spangenthal, et al.. (2011). Novel Combination Of Glycopyrrolate And Formoterol MDI (GFF-MDI) Provides Superior Bronchodilation Compared To Its Components Administered Alone, Tiotropium DPI, And Formoterol DPI In A Randomized, Double-Blind, Placebo-Controlled Phase 2b Study In Patients With COPD. A6435–A6435. 17 indexed citations

17.

Quinn, Dean, et al.. (2010). A Novel Formoterol Fumarate Metered Dose Inhaler Formulation Demonstrates Comparable Bronchodilator Efficacy Relative To Foradil® Aerolizer® And Favorable Safety Outcomes In Patients With COPD. A4458–A4458. 2 indexed citations

18.

Richards, Duncan, et al.. (2009). Treatment with a peroxisomal proliferator activated receptor gamma agonist has a modest effect in the allergen challenge model in asthma: A randomised controlled trial. Respiratory Medicine. 104(5). 668–674. 43 indexed citations

19.

Quinn, Dean, et al.. (2007). An audiovisual reminder function improves adherence with inhaled corticosteroid therapy in asthma. Journal of Allergy and Clinical Immunology. 119(4). 811–816. 142 indexed citations

20.

Büchsenschütz, Olivier, et al.. (1998). L'organisation spatiale de l'oppidum. Gallia. 55(1). 18–48. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact